Last reviewed · How we verify
RSV F subunit 45 μg No adjuvant — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
RSV F subunit 45 μg No adjuvant (RSV F subunit 45 μg No adjuvant) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| RSV F subunit 45 μg No adjuvant TARGET | RSV F subunit 45 μg No adjuvant | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- RSV F subunit 45 μg No adjuvant CI watch — RSS
- RSV F subunit 45 μg No adjuvant CI watch — Atom
- RSV F subunit 45 μg No adjuvant CI watch — JSON
- RSV F subunit 45 μg No adjuvant alone — RSS
Cite this brief
Drug Landscape (2026). RSV F subunit 45 μg No adjuvant — Competitive Intelligence Brief. https://druglandscape.com/ci/rsv-f-subunit-45-g-no-adjuvant. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab